Clinical trial · Observational
Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
A Prospective, Multi-centered Study to Assess the Complication Rates of Oncology Patients Accessed With Peripheral Intravenous Lines Versus Implantable Ports for Chemotherapy Administration
NCT02792764CI-TRIAL-00022521VEINSFORLIFEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to collect current information on complications rates of subjects undergoing chemotherapy administration through Ports and peripheral IVs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PORTs/Peripheral IVs Complication Rates | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Port
- description
- Subjects receiving chemotherapy through a port
- label
- Peripheral Intravenous (PIV) Lines
- description
- Subjects receiving chemotherapy through a peripheral IV
Primary outcomes (1)
- measure
- The rate of adverse events in subjects undergoing chemotherapy administration through PORTs and PIVs.
- timeFrame
- Through end of chemotherapy, up to 3 years
- description
- Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications
Secondary outcomes (3)
- measure
- The average number of accesses during course of treatment (i.e. - chemotherapy administration, CTs, blood draws, TPN, etc.)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female, age ≥ 21 years * Subject is currently undergoing or has had infusional cancer therapy (solid tumor or hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter or infusion through a PIV * Subject had a chemotherapy regimen consisting of a vesicant and/or irritant * Subject has signed an Informed Consent Form (ICF) or has had an ICF signed by the subject's legally authorized representative Exclusion Criteria: * Subject has/had an implanted non Bard PORT
References
Publications (0)
Data not yet available
No reference posted for this study.